PureCycle Technologies launched a dual $395-million underwritten offering of convertible senior notes and common stock to ...
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate ...
PureCycle Technologies, Inc. (“PureCycle” or the “Company”) (NASDAQ: PCT) today announced the closing of its previously announced public offerings of $287.5 million aggregate principal amount of its 4 ...
DENVER--(BUSINESS WIRE)-- Advanced Energy Industries, Inc. (“Advanced Energy”) (Nasdaq: AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, ...
Keel Infrastructure (KEEL) has priced its public offering of 1.250% convertible senior notes due 2032 at an aggregate principal amount of $400M. Due to strong market demand, the offering was upsized ...
StockStory.org on MSN
Why Bandwidth (BAND) stock is trading lower today
What Happened? Shares of cloud communications provider Bandwidth (NASDAQ:BAND) fell 12.7% in the morning session after the ...
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced the pricing of its offering of $600.0 million aggregate principal amount of 0.00% convertible ...
10don MSN
Why Ciena Stock Stumbled Today
It's floating a large-scale convertible notes issue.
ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced the pricing of $550 million aggregate principal amount of its ...
Ciena ® Corporation (NYSE: CIEN) (the "Company"), the global leader in high-speed connectivity, today announced that it intends to offer $2.0 billion aggregate principal amount of convertible senior ...
Amkor Technology, Inc. (Nasdaq: AMKR) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2031 ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results